Creating pathways to navigate patient care

In June, the AAD released an update to its Guidelines of Care for the Management of Actinic Keratosis (AK) to reflect tirbanibulin research.

The guideline update, published in JAAD, focuses on the strongly recommended use of tirbanibulin, a first-in-class microtubule inhibitor recently approved by the FDA to treat actinic keratoses. This is the AAD’s first focused update to a guideline and represents a novel guidance development process for the AAD focused on producing timely updates to current AAD guidance in light of new, potentially practice-changing evidence. The guidance issued in the focused update is intended to update the existing, recently published AAD Guidelines of Care for the Management of Actinic Keratosis.

For the focused update, the guideline workgroup performed a systematic review of data on the use of tirbanibulin for the treatment of AKs, identifying two relevant studies. Analysis of the evidence resulted in a strong recommendation for the use of topical tirbanibulin as field therapy for AKs. Check out the updated guidelines (PDF).